Mercer Global Advisors
PTCT icon

Mercer Global Advisors’s PTC Therapeutics PTCT Stock Holding History

Mercer Global Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.43M Buy
50,357
+36,926
+275% +$2.61M 0.01% 938
2025
Q4 		$1.02M Sell
13,431
-954
-7% -$69.3K ﹤0.01% 1445
2025
Q3 		$883K Buy
+14,385
New +$749K ﹤0.01% 1446

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Mercer Global Advisors's PTCT Position: Q1 2026 in Review

Mercer Global Advisors increased its PTC Therapeutics (PTCT) stake by 275% in Q1 2026, buying an estimated $2.61M and bringing the position to 50,357 shares worth $3.43M. The position accounts for 0.01% of the portfolio, ranked #938.

Mercer Global Advisors first reported a position in PTCT in Q3 2025 and has held it in 3 quarters since. 350 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Mercer Global Advisors held 50,357 shares of PTC Therapeutics worth $3.43M as of Q1 2026.
  • Mercer Global Advisors bought 36,926 PTC Therapeutics shares in Q1 2026, an estimated $2.61M.
  • PTC Therapeutics made up 0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #938 holding.
  • Mercer Global Advisors first reported a position in PTC Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 350 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.